Your body cannot make zinc — every atom of it must come through your intestine. ZIP4¹¹ ZIP4
Zinc/Iron-regulated transporter-like Protein 4, encoded by SLC39A4, is the dominant apical zinc importer in duodenal and jejunal enterocytes, the protein encoded by SLC39A4, sits at the brush border of the small intestine and acts as the primary gateway for dietary zinc absorption. When both copies of SLC39A4 carry loss-of-function variants, zinc simply cannot get in — and the resulting deficiency is profound and life-threatening without treatment.

This SNP, rs121434290, captures a missense change at codon 106 that replaces asparagine with lysine (p.Asn106Lys). The variant was first reported in a compound heterozygous French family²² compound heterozygous French family
Küry S et al. Identification of SLC39A4, a gene involved in acrodermatitis enteropathica. Nat Genet, 2002, where one chromosome carried this missense change and the other carried an approximately 2-kb upstream deletion that abolished gene expression. The compound heterozygosity was sufficient to cause full acrodermatitis enteropathica (AE)³³ acrodermatitis enteropathica (AE)
A rare autosomal recessive disorder of zinc malabsorption presenting with the classic triad of periorificial and acral dermatitis, chronic diarrhea, and alopecia; incidence ~1 in 500,000 newborns globally.

The Mechanism

ZIP4 is a transmembrane zinc transporter with eight predicted membrane-spanning domains and an extracellular amino-terminal domain that is essential for function. Asparagine 106 lies within this extracellular domain⁴⁴ extracellular domain
The N-terminal ectodomain of ZIP4 folds into a petal-like structure that binds zinc and facilitates its delivery to the transmembrane channel. Under zinc-replete conditions, this domain is proteolytically shed as a regulatory response; under zinc-deficient conditions, the full-length protein is stabilized to maximize uptake and contributes to the folded structure required for zinc capture and channel opening. The Asn106Lys substitution disrupts normal ectodomain function — a 2009 molecular study⁵⁵ 2009 molecular study
Mao X et al. Novel proteolytic processing of the ectodomain of the zinc transporter ZIP4 (SLC39A4) during zinc deficiency is inhibited by acrodermatitis enteropathica mutations. J Biol Chem, 2009 demonstrated that several AE-causing missense mutations, including variants at conserved positions in this domain, block the regulated proteolytic cleavage that normally fine-tunes ZIP4 surface expression in response to dietary zinc availability.

When both ZIP4 alleles are non-functional, zinc absorption in the duodenum and proximal jejunum falls to near zero. Zinc is required as a cofactor for over 300 enzymes and 2,000 transcription factors; its loss disrupts epithelial integrity, T-cell function, wound healing, and cell division. Serum zinc drops below 7 μmol/L (normal 9.8-16.8 μmol/L), and alkaline phosphatase — a zinc-dependent enzyme — is a reliable early marker of deficiency.

The Evidence

SLC39A4 was identified simultaneously by two groups in 2002: Küry et al. in Nature Genetics and Wang et al. in the American Journal of Human Genetics, reporting mutations in eight and five AE families respectively. Since then, a 2009 systematic update⁶⁶ 2009 systematic update
Schmitt S et al. An update on mutations of the SLC39A4 gene in acrodermatitis enteropathica. Hum Mutat, 2009 catalogued over 31 distinct mutations spread across the entire gene — missense, nonsense, frameshift, splice-site, and large deletions — with no clear genotype-phenotype correlation between specific mutation type and clinical severity. The N106K missense variant (this SNP) is one of the founding pathogenic variants described in that initial discovery.

Carrier parents of AE children are uniformly asymptomatic for zinc deficiency under normal dietary conditions. Mouse studies suggest heterozygous Zip4 animals are approximately 10 times more sensitive to zinc deficiency during pregnancy than wild-type littermates (Dufner-Beattie et al. Human Mol Genet, 2007⁷⁷ Dufner-Beattie et al. Human Mol Genet, 2007), but this has not been translated into clinically actionable guidance for human carriers at normal dietary zinc intake.

Treatment with oral zinc supplementation (3 mg/kg/day elemental zinc, typically as zinc sulfate) is dramatically effective in homozygous patients, with clinical improvement within days and full symptom resolution within weeks. StatPearls AE review⁸⁸ StatPearls AE review cites a 100% response rate with adequate zinc replacement; without treatment, the condition is fatal within early childhood.

Practical Actions

For carriers (GT genotype): carrier status has implications for family planning and genetic screening of at-risk relatives, but does not ordinarily require dietary zinc adjustment. Serum zinc monitoring is warranted during pregnancy due to the heightened zinc demands of fetal development.

For homozygous individuals (TT genotype): lifelong oral zinc supplementation is mandatory. Monitoring must include not only plasma zinc but also serum copper — chronic high-dose zinc competitively inhibits copper absorption through shared transport proteins, and copper deficiency can develop silently. Alkaline phosphatase activity is a useful surrogate marker reflecting the zinc status of both bone and intestinal tissue.

Interactions

Because AE is autosomal recessive, a second loss-of-function SLC39A4 variant must be present on the other chromosome for full disease expression. Clinical sequencing of AE patients typically reveals compound heterozygosity for two different mutations — as in the original family where this N106K variant paired with a promoter deletion. This means a person carrying this variant and a different SLC39A4 pathogenic variant in trans would be clinically affected even though neither individual variant is homozygous. Comprehensive SLC39A4 gene sequencing (not just SNP genotyping) is needed for complete clinical evaluation.

The PTPN22 gene is widely known for its R620W variant (rs2476601), one of the strongest non-HLA autoimmune risk factors. But R620W is not the only functional player in this locus. Deep sequencing and haplotype studies have revealed that multiple independent signals exist within PTPN22¹¹ multiple independent signals exist within PTPN22
Haplotype analysis of 37 SNPs identified two additional PTPN22 variants associated with RA independent of R620W, each potentially influencing immune regulation through different mechanisms. rs1217414 is one such secondary variant — an intronic SNP that has been associated with psoriasis, ankylosing spondylitis, and autoimmune conditions in populations where R620W is effectively absent.

The Mechanism

rs1217414 sits within an intron of PTPN22 at GRCh38 chromosome 1 position 113,870,044. PTPN22 is transcribed on the minus strand, so genome files report the plus-strand alleles (G/A), while many publications report the complementary coding-strand alleles (C/T). The G allele (plus strand) corresponds to C on the coding strand; the A allele (plus strand) corresponds to T. As an intronic variant, rs1217414 has no direct effect on protein sequence. Its functional impact is most likely regulatory — intronic variants can affect splicing efficiency, create or destroy binding sites for splicing factors, or alter local chromatin accessibility²² regulatory — intronic variants can affect splicing efficiency, create or destroy binding sites for splicing factors, or alter local chromatin accessibility
Intronic variants near exon-intron boundaries or within regulatory elements can modulate mRNA splicing and transcription factor binding, altering PTPN22 expression level or isoform ratios in immune cells.

The low LD between rs1217414 and R620W³³ low LD between rs1217414 and R620W
The psoriasis study found rs2476601 showed no association when rs1217414 was significantly associated, indicating these two signals are largely independent means this variant captures PTPN22 biology not tagged by the classic risk allele. In populations of East Asian ancestry, where R620W is nearly absent (~1% MAF), rs1217414 represents the primary accessible PTPN22 risk signal, explaining why multiple Chinese-population studies examined this SNP specifically.

The Evidence

The most compelling evidence comes from Smith et al. 2008⁴⁴ Smith et al. 2008
Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. Br J Dermatol, 2008, who genotyped 647 Type I psoriasis patients and 566 controls, then replicated in a combined dataset of 900 patients and 2,590 controls. rs1217414 demonstrated significant association (P=0.003) and the signal held when adjusted for rs2476601, confirming independence. Crucially, R620W showed no association with psoriasis at all, while rs1217414 did — a pattern that is the inverse of what is seen in rheumatoid arthritis, where R620W dominates.

In a Chinese Han cohort, Wang et al. 2015⁵⁵ Wang et al. 2015
Association of PTPN22 polymorphisms and ankylosing spondylitis susceptibility. Int J Clin Exp Pathol, 2015 found the T allele (A on plus strand) conferred substantial risk for ankylosing spondylitis (OR=2.13 for heterozygotes, OR=5.79 for homozygotes) — an additive dose-response pattern. The allele frequency in controls was ~10.5%, close to the 8% MAF in East Asian populations from dbSNP.

A large-scale Chinese Han study by Tang et al. 2016⁶⁶ Tang et al. 2016
PTPN22 polymorphisms, but not R620W, were associated with genetic susceptibility of SLE and RA in a Chinese Han population. Hum Immunol, 2016 found the same T allele (A plus strand) to be protective against both SLE (OR=0.57, padj=6×10⁻⁴; 713 cases, 672 controls) and RA (OR=0.26, padj=2×10⁻⁸; 358 cases, 564 controls). This may appear contradictory to the AS risk data, but these studies used different populations and examined different autoimmune conditions with distinct immune pathologies. The direction of effect at non-coding regulatory variants can differ by tissue context, disease type, and LD background.

In European-Americans with SLE, Namjou et al. 2013⁷⁷ Namjou et al. 2013
PTPN22 association in SLE with respect to individual ancestry and clinical sub-phenotypes. PLoS One, 2013 identified rs1217414 as an independent secondary signal alongside rs2476601, specifically in European-Americans. Neither SNP showed independent association in African-Americans or Asian-Americans.

The overall picture is moderate-evidence⁸⁸ moderate-evidence
Evidence is replicated across multiple independent studies and populations but with inconsistent direction of effect across conditions, preventing clinical-grade classification: this variant genuinely influences PTPN22-mediated immune regulation, but its directional effects differ by disease context, population background, and LD architecture.

Practical Implications

If you carry one or two copies of the A allele (GA or AA genotype), your PTPN22 regulatory activity may differ from the population average in ways that modulate autoimmune susceptibility — specifically for psoriasis and spondyloarthropathy risk. Unlike R620W, this variant does not have established associations with rheumatoid arthritis or type 1 diabetes in European populations, so the monitoring priorities differ.

The most clinically actionable finding is the psoriasis signal: if you have a personal or family history of psoriasis, early-onset skin or joint symptoms warrant dermatology evaluation. Psoriatic arthritis — the inflammatory joint disease that affects about 30% of people with psoriasis — often begins with skin disease and can progress silently before joint symptoms become prominent. PTPN22 variants have also been implicated in ankylosing spondylitis, a form of axial spondyloarthropathy; unexplained back pain with inflammatory features (morning stiffness, worsening at rest) in carriers is worth evaluating.

Interactions

The key interaction context is with rs2476601 (R620W), the primary PTPN22 variant. rs1217414 is largely independent of R620W — the two SNPs tag different haplotypes and likely different functional mechanisms. In Europeans, someone carrying both rs1217414-A and rs2476601-A faces cumulative PTPN22 dysregulation from two independent axes. In East Asian populations where R620W is rare, rs1217414 becomes the primary PTPN22 signal.

Within the psoriasis signal, rs1217414 was found to interact with rs3789604 — carrying risk alleles at both SNPs showed stronger combined association (P=0.002) than either alone, suggesting haplotype-level effects on PTPN22 regulation. rs3789604 is a nearby PTPN22 variant also in the database; together these may define a psoriasis-specific haplotype distinct from the R620W haplotype that drives RA and T1D risk.

Antithrombin — encoded by SERPINC1 on chromosome 1 — is the principal brake on coagulation. It is a serpin¹¹ serpin
serine protease inhibitor: a family of proteins that regulate coagulation, fibrinolysis, and inflammation by acting as decoy substrates for serine proteases that permanently inactivates thrombin and Factor Xa, the two enzymes most responsible for generating fibrin clot. Without functional antithrombin, coagulation runs unchecked at the slightest provocation. The Ser148Pro variant (rs121909569) in SERPINC1 substitutes proline for serine at position 148, altering the protein's conformation in a way that impairs both its heparin-binding capacity and its reactive site — a dual defect that defines type II pleiotropic effect (type II-PE) antithrombin deficiency²² type II pleiotropic effect (type II-PE) antithrombin deficiency
The most clinically severe subtype: type I reduces antigen and activity equally; type II-HBS reduces heparin binding only; type II-PE reduces both heparin-dependent and heparin-independent anticoagulant activity.

The Mechanism

Antithrombin inhibits its target proteases through a conformational mechanism called the serpin suicide substrate pathway. The reactive site loop — the region that presents itself as a decoy peptide to thrombin and Factor Xa — must be positioned correctly, and heparin binding dramatically accelerates the inhibitory reaction by bridging antithrombin to its targets. The Ser148Pro substitution introduces a proline residue into a region of the protein that connects the heparin-binding domain to the reactive site loop. Proline is conformationally rigid — it eliminates a peptide bond rotational degree of freedom that other amino acids allow — and its insertion at position 148 disrupts the transmission of the conformational change that heparin binding normally induces. The result is impaired heparin-dependent acceleration AND reduced baseline reactive site efficiency³³ impaired heparin-dependent acceleration AND reduced baseline reactive site efficiency
Pleiotropic effect classification: affects both the heparin-binding arm and the reactive site — the two mechanisms by which antithrombin inactivates thrombin and Factor Xa. Plasma antithrombin activity and antigen levels typically fall to 40–60% of normal in heterozygous carriers, leaving half the normal coagulation brake.

Homozygous antithrombin deficiency has not been reported in viable offspring, suggesting complete absence of antithrombin activity is incompatible with survival — underscoring how essential this protein is to basic hemostasis.

The Evidence

A 2024 systematic review and meta-analysis by Alnor et al.⁴⁴ 2024 systematic review and meta-analysis by Alnor et al.
39167180: Anne Alnor, Annals of Hematology — pooled data across multiple cohort studies of hereditary thrombophilia placed antithrombin deficiency at an odds ratio of 4.01 (95% CI 2.50–6.44) for venous thromboembolism — intermediate between homozygous Factor V Leiden (OR 5.58) and heterozygous Factor V Leiden (OR 2.97). This positions AT deficiency as a high-impact inherited thrombophilia, albeit with wide confidence intervals reflecting the rarity of prospective cohort data.

A review of hereditary antithrombin deficiency treatment⁵⁵ review of hereditary antithrombin deficiency treatment
Rodgers GM, Thromb Haemost 2009 synthesized earlier cohort data and estimated a ≥50% lifetime risk of VTE in confirmed AT-deficient individuals — three to seven times higher than the residual risk associated with other thrombophilias such as protein C or protein S deficiency. Antithrombin levels in heterozygous carriers typically run at 40–60% of normal — an unusually severe haploinsufficiency for a dominant variant.

The pregnancy-specific risk is particularly elevated⁶⁶ particularly elevated
Croles et al. BMJ 2017 Bayesian meta-analysis; RCT-level data are unavailable for ethical reasons, so Bayesian modeling of observational studies provides the best evidence: antithrombin deficiency carries an estimated 7.3% antepartum VTE risk (95% credible interval 1.8–15.6%) and 11.1% postpartum risk (3.7–21.0%). These absolute risks are among the highest of any inherited thrombophilia and drive the ACOG and ACCP recommendations for anticoagulant prophylaxis in affected pregnant women.

In a population-based cohort of 29,387 middle-aged Swedish adults⁷⁷ population-based cohort of 29,387 middle-aged Swedish adults
Manderstedt et al. JAHA 2022; Malmö Diet and Cancer cohort followed from 1991–2018, SERPINC1 disease-causing mutation carriers had a hazard ratio of 1.6 (95% CI 1.3–1.9) for incident VTE. This real-world unselected population estimate is lower than estimates from thrombophilia clinic cohorts (which select for symptomatic families), providing a more conservative but more generalizable risk figure.

Practical Actions

For heterozygous carriers of Ser148Pro, the clinical priorities are: documentation and disclosure (this result must be in medical records before any surgery, hospitalization, pregnancy, or hormonal therapy); thrombophilia specialist evaluation; and avoidance of high-risk provoking exposures. Routine (unprovoked) anticoagulation is not indicated for asymptomatic carriers, but high-risk situational prophylaxis during surgery, immobility, and pregnancy is strongly supported. Women considering combined hormonal contraceptives face multiplicative risk and should choose non-estrogen methods. Hematology consultation should precede any high-stakes decisions. First-degree relatives carry a 50% chance of inheriting the variant and benefit from cascade genetic testing before their first thrombotic event.

Interactions

The most clinically significant interaction is with Factor V Leiden (rs6025, F5 R506Q)⁸⁸ Factor V Leiden (rs6025, F5 R506Q)
The most common inherited thrombophilia, affecting ~5% of Europeans; compound heterozygosity with AT deficiency has been associated with much higher VTE risk than either alone. Double thrombophilia — inheriting both an antithrombin mutation and Factor V Leiden — produces additive or synergistic risk elevation. The prothrombin G20210A variant (rs1799963) represents a second compounding thrombophilic interaction. Any AT-deficient individual found to co-inherit one of these variants should have risk discussed by a hematologist as a combined clinical picture, not as two separate genetic findings.

Inside every neuron that makes dopamine or serotonin, a small enzyme called sepiapterin reductase (SPR) performs the final step in synthesising tetrahydrobiopterin¹¹ tetrahydrobiopterin
BH4 — an essential cofactor for three key enzymes in neurotransmitter production. Without sufficient BH4, the enzymes that convert tyrosine into dopamine and tryptophan into serotonin grind to a halt. The Q119X variant in SPR — a single nucleotide change that replaces glutamine at position 119 with a premature stop codon — creates a truncated, non-functional protein and is the cause of SPR deficiency (OMIM #612716), a rare but fully treatable neurological disorder.

The Mechanism

BH4 acts as a cofactor for phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), and tryptophan hydroxylase (TPH). TH and TPH are the rate-limiting enzymes for dopamine and serotonin synthesis respectively. SPR catalyses the reduction of 6-pyruvoyltetrahydropterin to BH4 in the final step of de novo synthesis²² SPR catalyses the reduction of 6-pyruvoyltetrahydropterin to BH4 in the final step of de novo synthesis
sepiapterin reductase is an aldo-keto reductase encoded on chromosome 2p13.2. The Q119X nonsense mutation (c.355C>T, NM_003124.5) truncates the protein at codon 119, abolishing enzyme activity in skin fibroblasts. Peripheral tissues can partially compensate via alternative reductases (aldose reductase, carbonyl reductase, dihydrofolate reductase), but the brain relies predominantly on SPR — explaining why SPR deficiency is neurologically devastating while plasma phenylalanine remains normal, causing it to be invisible to standard PKU neonatal screening³³ invisible to standard PKU neonatal screening
SPR deficiency does not elevate blood phenylalanine, the marker used in universal newborn screening.

The Evidence

Bonafé et al. (2001)⁴⁴ Bonafé et al. (2001) first characterised Q119X in a consanguineous Turkish family: a 14-year-old male homozygous for the variant had psychomotor retardation, spasticity, dystonia, and severely reduced CSF levels of the dopamine metabolite homovanillic acid (HVA) and the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA), with elevated biopterin. Clinical improvement followed levodopa treatment.

Friedman et al. (2012)⁵⁵ Friedman et al. (2012) described 38 patients with confirmed SPR deficiency across 11 countries. Average symptom onset was 7 months, but average time to diagnosis was 9.1 years — most patients were misdiagnosed as having cerebral palsy. The defining features were axial hypotonia, dystonia, oculogyric crises, and diurnal fluctuation (worse in the evening, better after sleep). Patients improved dramatically on levodopa/carbidopa, with further benefit from adding 5-hydroxytryptophan.

GeneReviews (Friedman & Galosi, updated 2025)⁶⁶ GeneReviews (Friedman & Galosi, updated 2025) confirms autosomal recessive inheritance and notes that early treatment — ideally within the first year of life — can reverse developmental delay and prevent permanent cognitive impairment. Levodopa is dosed at 0.1–16 mg/kg/day combined with carbidopa or benserazide; 5-HTP at 1–6 mg/kg/day.

Heterozygous carriers of Q119X are clinically asymptomatic. A population study in Malta — where the carrier frequency reaches ~4–5% due to a founder effect — found that all carrier parents showed no clinical symptoms despite carrying one defective copy of the gene. Farrugia et al. 2007⁷⁷ Farrugia et al. 2007.

Practical Actions

For homozygous individuals (TT) the situation is a medical emergency requiring specialist care. The standard treatment is levodopa/carbidopa plus 5-HTP under neurological supervision, with remarkable outcomes when started early. For heterozygous carriers (CT), current evidence does not support any supplement protocol — carriers are phenotypically normal. The main practical value of knowing carrier status is for reproductive planning: two CT carriers have a 25% chance of an affected (TT) child per pregnancy.

Interactions

SPR deficiency shares its pathway with GTP cyclohydrolase I deficiency (GCH1 mutations, the dominant form of DOPA-responsive dystonia) and other BH4 biosynthesis disorders. All these conditions converge on the same downstream deficiency of dopamine and serotonin. SPR also interacts with the nitric oxide synthase pathway — BH4 is a cofactor for NOS enzymes, so severe SPR deficiency secondarily impairs nitric oxide production, contributing to autonomic dysfunction seen in roughly half of patients.

HLA-C¹¹ HLA-C
Human leukocyte antigen C is a class I MHC gene encoding a cell-surface protein that presents intracellular peptides to CD8+ T cells, allowing the immune system to distinguish self from non-self and from infected or aberrant cells sits at the heart of the psoriasis story. The rs12191877 SNP is a tag variant²² tag variant
A tag SNP doesn't cause disease itself but travels in tight linkage disequilibrium with the functional allele due to shared inheritance, serving as a reliable marker for it for the HLA-C*06:02 allele (historically called HLA-Cw6), the most strongly replicated genetic risk factor for psoriasis ever identified. Unusually for a common disease, this single allele accounts for roughly 35-50% of the genetic contribution³³ 35-50% of the genetic contribution
PSORS1 locus on chromosome 6p21.3 explains the majority of genetic variance in psoriasis; HLA-C*06:02 is the primary susceptibility variant within PSORS1 to disease risk—far exceeding the contribution of any other locus.

The Mechanism

Psoriasis is now understood to be a primary autoimmune disease directed against melanocytes⁴⁴ autoimmune disease directed against melanocytes
Melanocytes are the pigment-producing cells of the epidermis; in psoriasis, CD8+ T cells attack them through HLA-C*06:02-restricted antigen presentation—not merely an inflammatory skin condition. HLA-C*06:02 presents the melanocyte-derived peptide ADAMTSL5⁵⁵ ADAMTSL5
ADAMTS-like protein 5, a secreted glycoprotein expressed specifically in melanocytes; when processed and presented by HLA-C*06:02, it triggers a CD8+ T cell response that drives psoriatic inflammation to CD8+ T cells in the epidermis, triggering the signature IL-17A-driven inflammatory cascade that leads to keratinocyte hyperproliferation and the characteristic scaly plaques. The ERAP1⁶⁶ ERAP1
Endoplasmic reticulum aminopeptidase 1; trims peptides before loading onto HLA class I molecules. ERAP1 variants affect how much ADAMTSL5 peptide is generated for HLA-C*06:02 presentation aminopeptidase controls the supply of this autoantigenic peptide, explaining the well-documented epistatic interaction between HLA-C and ERAP1 variants in psoriasis GWAS.

The gene-dose effect is biologically meaningful. Heterozygous carriers express HLA-C*06:02 on fewer antigen-presenting cells than homozygotes, generating a weaker and less sustained T-cell response. This produces the graded risk seen clinically: homozygotes have substantially higher lifetime risk and earlier onset than heterozygotes.

The Evidence

Feng et al.⁷⁷ Feng et al.
Feng BJ et al. Multiple loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet. 2009;5(8):e1000606 performed a large GWAS identifying rs12191877 as the most significant single SNP (OR 2.92, p=3×10⁻⁵³), but demonstrated that imputed HLA-Cw*0602 dosage showed even stronger association (OR 3.85, p=8×10⁻⁶¹), confirming rs12191877 as a tag for the true causal allele rather than the functional variant itself.

Strange et al.⁸⁸ Strange et al.
Strange A et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42(11):985-990 extended this with 2,622 cases and 5,667 controls from the UK and Ireland, identifying the related tag rs10484554 at OR 4.66 (p=4×10⁻²¹⁴)—among the strongest single-variant associations documented in common disease GWAS. The same study demonstrated the epistatic interaction: ERAP1 variants only influenced psoriasis risk in HLA-C risk allele carriers⁹⁹ ERAP1 variants only influenced psoriasis risk in HLA-C risk allele carriers
Stratified analysis showed ERAP1 OR 1.43 in HLA-C risk carriers vs. no effect in non-carriers, combined p=6.95×10⁻⁶.

The clinical phenotype data are striking. Chen and Tsai¹⁰¹⁰ Chen and Tsai
Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854-862 reviewed decades of studies showing that HLA-Cw6 (HLA-C*06:02) consistently associates with type I early-onset psoriasis (peak ages 18-22), guttate morphology, Koebner phenomenon, positive family history, and reduced nail involvement compared to HLA-Cw6-negative disease. In populations studied for guttate psoriasis specifically, HLA-Cw6 prevalence reaches 73-100% of affected individuals.

The streptococcal trigger connection is also HLA-dependent. Mallbris et al.¹¹¹¹ Mallbris et al.
Mallbris L et al. HLA-Cw*0602 associates with a twofold higher prevalence of positive streptococcal throat swab at the onset of psoriasis. BMC Dermatol. 2009;9:5 found that HLA-Cw*0602-positive patients showed twice the rate of positive streptococcal throat cultures at disease onset (OR 3.5 for guttate, OR 2.3 for plaque psoriasis), consistent with molecular mimicry between streptococcal and skin antigens.

Practical Actions

The most actionable implication of HLA-C*06:02 status is biologic selection. Dand et al.¹²¹² Dand et al.
Dand N et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120-2130 analyzed 1,326 patients receiving adalimumab or ustekinumab and found that HLA-C*06:02-negative patients responded significantly better to adalimumab than ustekinumab at all timepoints (OR 2.95 at 6 months; OR 5.98 in those with concomitant psoriatic arthritis). HLA-C*06:02-positive patients without psoriatic arthritis showed poorer adalimumab response at 12 months. For ustekinumab specifically, Van Vugt et al.¹³¹³ Van Vugt et al.
Van Vugt LJ et al. Association of HLA-C*06:02 status with differential response to ustekinumab. JAMA Dermatol. 2019;155(6):708-715 confirmed in a meta-analysis of 8 studies (1,048 patients) that HLA-C*06:02-positive patients achieve 89% vs. 62% PASI75 response at 6 months. Secukinumab (anti-IL-17A) efficacy is high regardless of HLA-C*06:02 status, making it a reasonable choice for either genotype.

For TT homozygotes in particular, the elevated lifetime risk warrants dermatology awareness, prompt evaluation when skin changes appear, and advance discussion of treatment options before disease becomes severe.

Interactions

The documented ERAP1 epistasis is the most important gene-gene interaction here. ERAP1 risk haplotypes (particularly Hap2) compound the psoriasis risk in HLA-C*06:02 carriers by generating more autoantigenic ADAMTSL5 peptide for HLA-C*06:02 presentation. ERAP1 protective haplotypes (Hap10) reduce melanocyte immunogenicity even in HLA-C*06:02 carriers. This interaction explains why not all HLA-C*06:02 carriers develop psoriasis. At the population level, the GWAS-defined epistasis is confined largely to disease onset between ages 10-20, suggesting genetic heterogeneity within childhood-onset psoriasis. rs2187668 (HLA-DQA1 — DQ2.5 tag) shares the same chromosomal region on 6p21, reflecting the complex multi-locus HLA architecture governing multiple immune-mediated diseases at this locus.

BNC2 encodes basonuclin-2, a zinc finger transcription factor¹¹ zinc finger transcription factor
A protein that reads and controls gene activity using zinc-coordinated finger-shaped domains that is expressed in melanocytes and plays an essential role in supporting the survival and patterning of pigment-producing cells. Unlike the better-known pigmentation genes (MC1R, TYR, OCA2) that act directly within melanocytes, BNC2 operates partly through the extracellular environment in which melanocytes reside. The variant rs12350739 sits not inside BNC2 itself, but in a conserved intergenic enhancer approximately 130 kilobases upstream of the BNC2 gene body. This regulatory element acts as a dimmer switch: depending on which allele you carry, it controls how actively BNC2 is transcribed in melanocytes, which in turn modulates the saturation of skin pigmentation²² saturation of skin pigmentation
The richness or intensity of melanin color, distinct from overall hue — how deeply pigmented the skin appears, and how prone it is to freckling and age-related pigmented spots.

The Mechanism

The highly conserved region surrounding rs12350739 functions as an allele-dependent enhancer³³ allele-dependent enhancer
A DNA regulatory sequence whose activity differs between the two allele variants that regulates BNC2 transcription in human melanocytes. When you carry the G allele, the chromatin at this locus is accessible: the enhancer is active, BNC2 is expressed at higher levels, and melanin production is robustly supported. When you carry the A allele, the same region shows inaccessible chromatin — the enhancer is only weakly active, BNC2 expression falls, and the downstream support for melanocyte function is reduced. The consequence at the phenotypic level is lighter, less saturated skin pigmentation and a tendency toward patchier, uneven melanin distribution — the biological substrate for freckling⁴⁴ freckling
Small concentrated deposits of melanin in skin cells, more visible with low overall pigmentation and age spots.

This is a regulatory variant, not a protein-coding change: BNC2 protein structure is unaltered, but its abundance in melanocytes is tuned by which allele is present. The effect scales with allele dosage — AA homozygotes show the lowest BNC2 expression and lightest pigmentation, AG heterozygotes are intermediate, and GG homozygotes show the highest expression and darkest pigmentation contribution from this locus.

The Evidence

The key mechanistic study was Visser, Palstra & Kayser 2014⁵⁵ Visser, Palstra & Kayser 2014
Human skin color is influenced by an intergenic DNA polymorphism regulating transcription of the nearby BNC2 pigmentation gene. Human Molecular Genetics, 23(21):5750–5760, which demonstrated through chromatin accessibility assays and reporter experiments that rs12350739 is the functional causal variant underlying the original BNC2 GWAS signal at rs10756819. The paper showed that A-allele chromatin is inaccessible at this locus, while G-allele chromatin is open and enhancer-active in human melanocytes, and that the A allele predominates in European populations (~57%), is rare in sub-Saharan Africans (~1%), and is essentially absent in East Asians.

The original GWAS signal at the BNC2 locus was identified in a Dutch candidate gene cohort of 5,860 individuals⁶⁶ Dutch candidate gene cohort of 5,860 individuals
rs10756819 associated with skin color saturation, p<0.05 in all cohorts where BNC2 variants were significantly associated with the saturation dimension of quantified skin color. A subsequent GWAS of facial pigmented spots in 2,844 Dutch Europeans⁷⁷ GWAS of facial pigmented spots in 2,844 Dutch Europeans
rs62543565, P=2.3×10⁻⁸, replicated in 599 individuals confirmed BNC2 at genome-wide significance for age-related facial lentigines and freckling, independent of background skin color — suggesting the gene's influence on melanin distribution goes beyond overall pigmentation level.

The skin cancer connection comes from a large GWAS of cutaneous squamous cell carcinoma (SCC)⁸⁸ large GWAS of cutaneous squamous cell carcinoma (SCC)
7,404 cases and 292,076 controls of European ancestry, in which the correlated BNC2 variant rs10810657 reached genome-wide significance (P=1.4×10⁻⁸, OR=0.90 for the T allele), confirming that the G-allele / high-BNC2 / darker-pigmentation haplotype carries a protective effect against SCC. Conversely, A-allele carriers — those with lighter, less saturated skin and lower BNC2 expression — show mildly elevated SCC risk.

Practical Implications

The clinical relevance of rs12350739 is primarily photoprotective. Carriers of two A alleles (AA genotype) have constitutionally lighter and less saturated skin, a genetic tendency toward freckling and age-related pigmented spots, and a modestly elevated susceptibility to UV-induced skin damage including squamous cell carcinoma. These individuals benefit from more rigorous daily sun protection and systematic dermatology surveillance than their GG counterparts. The A allele's high frequency in Europeans (~57%) means this is a common, not rare, variant — the majority of Europeans carry at least one A allele.

Importantly, the photoprotective deficit from this variant can be largely offset with consistent behavioral strategies: daily broad-spectrum sunscreen reduces UV-induced DNA damage independently of constitutive melanin levels. Freckling tendency itself is not medically harmful but serves as a visible indicator of lighter pigmentation and greater UV sensitivity in childhood — individuals who freckled heavily in youth often have higher cumulative UV exposure reflected in adult skin aging patterns.

Interactions

rs12350739 is in strong linkage disequilibrium (r²=0.90) with rs10810657, the SCC GWAS lead SNP at the BNC2 locus, meaning these variants are nearly always inherited together in Europeans. The nearby rs62543565 is independently associated with facial pigmented spot density. The rs10756819 intronic variant (the original GWAS proxy hit for skin saturation) is also in LD with rs12350739.

For melanoma risk, the BNC2 locus interaction with MC1R (rs1805007, rs1805008) is relevant: low-BNC2 AA carriers who also carry MC1R loss-of-function variants face a compounded photoprotective deficit, with lighter and less uniformly pigmented skin that burns easily. Similarly, concurrent carriage of SLC45A2 L374 allele (rs16891982 GG) and AA at BNC2 may have additive effects on reduced melanin. These interactions are observationally consistent with pigmentation pathway biology but specific combined-genotype effect sizes from adequately powered studies are not yet published.

In zebrafish, loss of bnc2⁹⁹ loss of bnc2
bnc2 mutant fish showing melanophore death and pigment fragmentation causes melanocytes, xanthophores, and iridophores to die and be extruded from the skin — a dramatic demonstration that this gene's non-autonomous support role in the extracellular niche is critical for pigment cell viability. The mammalian analog of this function, operating more subtly through enhancer regulation, may explain why reduced BNC2 expression biases toward patchier, less stable melanin distribution patterns rather than simple global depigmentation.

Glucokinase regulatory protein (GCKRP), encoded by the GCKR gene on chromosome 2, acts as the master brake on hepatic glucokinase (GCK), the enzyme responsible for the liver's glucose uptake after a meal. The rs1260326 Pro446Leu variant¹¹ rs1260326 Pro446Leu variant
Proline at position 446 is replaced by leucine in the GCKRP protein; this missense change arises from the T allele at genomic position chr2:27508073 on the plus strand is the functional coding variant that drives one of the most extensively replicated metabolic findings in human GWAS: a striking trade-off between lower fasting glucose and higher triglycerides.

This entry describes the direct coding variant. An intronic marker in the same region, rs780094²² rs780094
Intronic GCKR variant in r²=0.93 LD with rs1260326; historically genotyped as a proxy for P446L in early GWAS arrays, is also present in the GeneOps database and describes the same biological signal. If you carry the T allele at rs1260326, you almost certainly also carry the T allele at rs780094 — the two variants are nearly always co-inherited.

The Mechanism

The Pro446Leu substitution³³ Pro446Leu substitution
Proline-to-leucine change at codon 446 of GCKRP, encoded by the c.1337T allele in NM_001486.4; the T allele at genomic position 27508073 on the GRCh38 plus strand directly alters the regulatory domain of GCKRP in a way that impairs its response to fructose-6-phosphate (F6P). Under normal conditions, rising intracellular F6P signals GCKRP to re-sequester glucokinase in the nucleus, limiting further glucose phosphorylation. P446L-GKRP shows significantly reduced sensitivity to F6P at physiological concentrations (25–500 µM)⁴⁴ P446L-GKRP shows significantly reduced sensitivity to F6P at physiological concentrations (25–500 µM)
Biochemical assays show the P446L variant has statistically significantly reduced inhibitory responsiveness to F6P; the variant does not affect GCKRP's response to fructose-1-phosphate or its intrinsic inhibitory capacity. The feedback loop is weakened, leaving glucokinase constitutively more active.

Enhanced glucokinase activity drives greater glycolytic flux through the liver. The downstream products — malonyl-CoA and citrate — are the direct substrates for de novo lipogenesis⁵⁵ de novo lipogenesis
The liver's synthesis of fatty acids and triglycerides from carbohydrate precursors, which are packaged into VLDL and secreted into the bloodstream. This mechanistic chain explains the paradox: the same variant that improves glucose regulation simultaneously elevates circulating triglycerides and hepatic fat.

Because rs1260326 is a missense coding variant altering a specific amino acid in GCKRP, its functional consequences are more directly interpretable than those of the intronic proxy rs780094. Fine-mapping across 417 kb of the GCKR locus confirmed rs1260326 as the strongest association signal, with r²=0.93 with the previously studied rs780094.

The Evidence

The fine-mapping study establishing rs1260326 as the likely causal variant analyzed more than 45,000 individuals across 12 independent cohorts⁶⁶ more than 45,000 individuals across 12 independent cohorts
Orho-Melander et al. 2008, including Scandinavian, British, Dutch, and other European-ancestry populations. The T allele (Pro446Leu) at 34% global frequency was associated with higher fasting triglycerides (P=3×10⁻⁵⁶), lower fasting glucose (P=1×10⁻¹³), and elevated CRP (P=5×10⁻⁵). These associations replicate across virtually every cohort that has examined them, making this one of the best-characterized metabolic GWAS signals in the human genome.

The ARIC Study (n=14,889; 10,929 white, 3,960 Black)⁷⁷ ARIC Study (n=14,889; 10,929 white, 3,960 Black)
Atherosclerosis Risk in Communities Study; 45–64 years at baseline, prospective follow-up quantified the per-allele effects: −1.93 mg/dl fasting glucose (P=2.3×10⁻⁷), +0.16 mmol/l triglycerides (P=2.4×10⁻³¹), −0.45 HOMA-IR (P=2.2×10⁻⁹), and +0.56 mg/l CRP (P=1.6×10⁻⁸) in white participants. In Black participants, TG and insulin associations replicated (P=0.004 and P=0.002), while glucose and HOMA-IR associations did not, suggesting some ancestry-specific modulation of the phenotype.

A meta-analysis of five NAFLD studies (2,091 cases / 3,003 controls)⁸⁸ A meta-analysis of five NAFLD studies (2,091 cases / 3,003 controls)
Zain et al. 2014; both Asian and non-Asian populations represented found the T allele increases NAFLD risk with OR=1.25 (95% CI 1.14–1.36, P<0.00001). This is the mechanistic corollary of elevated triglycerides: excess hepatic lipogenesis deposits fat in the liver before it reaches the bloodstream as VLDL, progressively leading to steatosis. NAFLD can develop even in T allele carriers at normal body weight.

The cardiovascular picture is nuanced. The LURIC Study⁹⁹ LURIC Study
Ludwigshafen Risk and Cardiovascular Health Study; case-control of stable CAD patients; Kozian et al. 2010 found that despite significant elevations in plasma triglycerides and VLDL-TG, carriers of the GCKR T allele showed no association with coronary stenosis, myocardial infarction, left ventricular hypertrophy, or hypertension. This suggests the triglyceride particles generated by de novo lipogenesis may be larger, more buoyant, and less atherogenic than the small dense LDL implicated in classic atherosclerosis — but does not eliminate the need for monitoring, particularly given the NAFLD and CRP signals.

Practical Actions

The mechanistic specificity of P446L makes dietary fructose restriction the most targeted intervention. Because fructose enters the glycolytic pathway at fructose-1-phosphate (bypassing the rate-limiting phosphofructokinase step), it delivers carbon directly to the acetyl-CoA and citrate pool that feeds lipogenesis — and GCKRP's F6P feedback mechanism cannot compensate when it is already blunted by P446L. High-fructose loads in T allele carriers therefore produce proportionally greater hepatic triglyceride synthesis than in CC carriers.

Omega-3 fatty acids (EPA and DHA) specifically suppress hepatic VLDL-TG secretion and reduce de novo lipogenesis transcriptionally via PPAR-alpha and SREBP-1c pathways, directly addressing the downstream consequence of constitutively elevated glucokinase activity. Fasting triglyceride monitoring provides early detection of worsening lipid profiles. Given the NAFLD OR of 1.25, periodic liver enzyme surveillance (ALT, AST, GGT) is warranted even in the absence of other metabolic risk factors.

Relationship with rs780094 and Other Interactions

rs1260326 and rs780094 are in near-perfect linkage disequilibrium (r²=0.93) and represent the same biological signal. Genome-wide genotyping arrays historically assayed the intronic rs780094 more often than the coding rs1260326, so many earlier papers report rs780094 — but both variants tag the same P446L functional change. Users who have both variants genotyped should expect concordant results in ~93% of cases; the rare discordance reflects the LD imperfection, not a meaningful biological difference.

The GCK promoter variant [rs1799884 | −30G>A promoter variant in glucokinase itself; studied in Han Chinese for additive effects on fasting glucose with GCKR variants] operates in the same hepatic glucose-sensing regulatory complex. T allele carriers at both loci show additive fasting glucose reductions. This interaction is relevant because GCK and GCKR act in concert; functional variants in both could synergistically alter the liver's glucose-sensing setpoint.

The NAFLD risk from GCKR T allele carriers is substantially compounded by co-carriage of the PNPLA3 rs738409 G allele (an independent NAFLD risk variant), with dual carriers showing substantially higher hepatic steatosis burden than carriers of either variant alone. This is among the better-characterized gene-gene interactions in NAFLD genetics and represents a clinically important compound finding.

Lipoprotein lipase (LPL¹¹ LPL
the enzyme anchored to capillary walls in muscle and adipose tissue that breaks down triglycerides carried in VLDL and chylomicrons, releasing free fatty acids for energy use or storage) is the central enzyme in plasma triglyceride clearance. The variant rs12678919 sits in a regulatory region roughly 19 kilobases downstream of the LPL gene body. It is an intergenic tag SNP that marks a haplotype block associated with altered LPL expression or activity — the precise functional variant within this block has not been identified, but the association with LPL biology is unambiguous across dozens of independent studies.

The G allele at this position — carried by roughly one in ten people globally — consistently associates with lower circulating triglycerides and higher HDL cholesterol. Carriers of one or two G copies have meaningfully better lipid profiles than non-carriers, and Mendelian randomization analyses support a causal relationship between this LPL-locus variation and reduced cardiovascular risk.

The Mechanism

LPL hydrolyzes triglycerides from chylomicrons²² chylomicrons
particles that carry dietary fat from the intestine to peripheral tissues after a meal and VLDL³³ VLDL
very low-density lipoprotein, the liver's primary vehicle for exporting endogenous triglycerides into the circulation. As LPL processes these particles, the excess phospholipids and apolipoproteins shed from the shrinking particles are transferred to HDL — which is why higher LPL activity simultaneously lowers TG and raises HDL. The rs12678919 G allele appears to tag variants that sustain or enhance this LPL-mediated clearance, producing the dual benefit seen in GWAS.

Because the precise regulatory mechanism is not yet resolved, the exact functional change is described as regulatory rather than missense. Several candidate mechanisms include altered transcription factor binding in enhancer elements downstream of the gene, modified mRNA stability, or haplotype-level effects through linkage with coding variants such as rs328 (S447X, the well-studied gain-of-function variant) and rs10096633.

The Evidence

The association of rs12678919 with triglycerides and HDL is among the most robustly replicated findings in lipid genetics. Teslovich et al. (Nature, 2010)⁴⁴ Teslovich et al. (Nature, 2010)
Teslovich TM et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707–713 analyzed over 100,000 individuals and found rs12678919-G associated with a 13.64 mg/dL reduction in triglycerides (p=2×10⁻¹¹⁵) and a 2.25 mg/dL increase in HDL cholesterol (p=1×10⁻⁹⁷). The GLGC 2013 meta-analysis⁵⁵ GLGC 2013 meta-analysis
Willer CJ et al. Discovery and refinement of loci associated with lipid levels. Nature Genetics 2013;45:1274–1283 in over 188,000 participants confirmed rs12678919 as the lead signal for the LPL locus, with even stronger p-values reaching 2×10⁻¹⁹⁹ for TG. Both the HDL and TG associations replicated across European, East Asian, South Asian, and African American populations.

The LPL locus variants — including rs12678919 — have been incorporated into Mendelian randomization studies demonstrating a causal relationship between LPL-driven TG reduction and lower coronary artery disease risk. Nine LPL- associated SNPs collectively show consistently protective effects on CAD when modeled as instruments for TG-lowering.

Practical Actions

Carriers of the G allele have a naturally favorable lipid signature from this locus. This does not override all dietary or metabolic influences, but the LPL machinery at this locus is operating more efficiently. For carriers: the saturated fat and refined carbohydrate thresholds that trigger triglyceride elevation are effectively wider — the clearance system is more robust.

For the AA genotype (the common baseline): the locus is not conferring extra TG-clearing capacity. Dietary saturated fat raises TG more easily, and postprandial lipemia is cleared less rapidly. Targeted interventions — specifically omega-3 fatty acids at therapeutic doses, which up-regulate LPL activity, and limiting refined carbohydrates that drive hepatic VLDL-TG production — address this directly. A fasting lipid panel every 2–3 years from age 35 is reasonable baseline monitoring.

Interactions

rs12678919 is in partial LD with several other LPL-region SNPs including rs328 (S447X, the gain-of-function coding variant), rs10096633, rs17482753, and rs10503669. Conditional analyses indicate these represent partially independent signals within the same locus. Carrying rs328 X allele on the same haplotype as the rs12678919 G allele may produce additive TG-lowering, though the degree of LD means these variants co-occur more often than not in European populations.

The LPL locus interacts functionally with APOC3 (rs2854116, rs2854117): apoC-III inhibits LPL activity, and high APOC3 expression can override the benefit of a favorable LPL haplotype. Carriers of rs12678919 AA who also carry TG-raising APOC3 variants may see attenuated benefit from dietary interventions targeting LPL.

Most genetic thrombophilia testing focuses on the coagulation cascade: Factor V Leiden, prothrombin G20210A, antithrombin deficiency. These variants are clinically established but together account for fewer than half of all heritable VTE cases. rs13412535, a regulatory variant in the SERPINE2 gene, points to a parallel fibrinolytic control circuit — one involving Protease Nexin-1 (PN-1), a [serpin | serine protease inhibitor — a family of proteins that regulate proteolytic enzyme activity by acting as decoy substrates] expressed in platelets, vascular cells, and most tissues, but barely detectable in free plasma.

The Mechanism

SERPINE2 encodes Protease Nexin-1 (PN-1)¹¹ Protease Nexin-1 (PN-1)
a 50 kDa glycoprotein in the serpin superfamily, phylogenetically closest to PAI-1 (SERPINE1), the canonical fibrinolysis inhibitor. PN-1 does not simply mimic PAI-1 — it operates through a distinct and broader inhibitory spectrum. PN-1 inhibits thrombin with kinetics enhanced 1,000-fold by heparan sulfate proteoglycans on cell membranes and in extracellular matrix, making it the most efficient tissue-bound thrombin inhibitor known. Beyond thrombin, PN-1 suppresses urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), and plasmin — the very enzymes responsible for dissolving fibrin clots.

The consequence is profound: platelet PN-1 inhibits both the generation of plasmin by fibrin-bound tPA and the enzymatic activity of fibrin-bound plasmin itself, reducing the rate of fibrin degradation approximately 10-fold²² platelet PN-1 inhibits both the generation of plasmin by fibrin-bound tPA and the enzymatic activity of fibrin-bound plasmin itself, reducing the rate of fibrin degradation approximately 10-fold
Boulaftali et al. 2011 showed that antibody blockade of PN-1 in platelet-rich plasma fully restores tPA-mediated fibrinolysis that PN-1 had suppressed. PN-1 is thus a "lysis-resistance factor" for platelet-rich thrombi — the same type that form in veins under low-flow conditions.

rs13412535 is an intronic regulatory variant in SERPINE2. The A allele is the effect allele identified in the Thibord 2022 cross-ancestry GWAS; the most likely mechanism is altered SERPINE2 transcriptional regulation shifting PN-1 expression in platelets or vascular cells, though the exact cis-regulatory mechanism has not yet been resolved in functional studies.

The Evidence

Thibord et al. 2022 performed a cross-ancestry meta-analysis of 81,669 VTE cases across 30 studies (European, African, and Hispanic ancestry), identifying 135 independent genomic loci associated with VTE risk³³ Thibord et al. 2022 performed a cross-ancestry meta-analysis of 81,669 VTE cases across 30 studies (European, African, and Hispanic ancestry), identifying 135 independent genomic loci associated with VTE risk
The SERPINE2 locus was a novel replicated finding: rs13412535 A allele showed discovery OR 1.06 (p=3.05×10⁻¹⁰) and replication OR 1.08 (p=1.10×10⁻³⁶), with concordant effect direction across ancestry groups. The effect allele frequency was approximately 0.20 globally — meaning this variant is common, not rare, and contributes meaningfully to population-level VTE burden.

Ghouse et al. 2023 extended this to a genome-wide meta-analysis of 81,190 VTE cases and 1,419,671 controls across six cohorts, identifying 93 risk loci (62 previously unreported)⁴⁴ Ghouse et al. 2023 extended this to a genome-wide meta-analysis of 81,190 VTE cases and 1,419,671 controls across six cohorts, identifying 93 risk loci (62 previously unreported)
The study demonstrated that individuals in the top 0.1% of polygenic risk score — built partly on loci like SERPINE2 — face VTE risk comparable to carriers of homozygous or compound heterozygous monogenic thrombophilia mutations. This underscores that common low-effect variants like rs13412535 aggregate into clinically meaningful risk when combined.

The biological plausibility is supported by mouse knockout experiments: PN-1-deficient mice show dramatically accelerated vascular recanalization after tPA treatment — 92% recanalization within one hour versus 15% in wild-type mice — and spontaneously enhanced clot lysis without PN-1⁵⁵ PN-1-deficient mice show dramatically accelerated vascular recanalization after tPA treatment — 92% recanalization within one hour versus 15% in wild-type mice — and spontaneously enhanced clot lysis without PN-1
Boulaftali et al. 2011 used a dorsal skinfold chamber model with real-time intravital microscopy to quantify thrombolysis kinetics; recanalization in PN-1-null mice took 13±2 minutes vs over 60 minutes in wild-type. Increased PN-1 activity — the likely consequence of the A risk allele — mirrors the wild-type phenotype of enhanced clot lysis resistance.

Evidence level is strong: the GWAS finding has been replicated across ancestries at genome-wide significance with concordant effects, and the mechanistic biology of PN-1 in fibrinolytic control is extensively characterized. The specific cis-regulatory mechanism of rs13412535 has not been resolved by eQTL studies, placing it one step below established.

Practical Actions

The per-allele OR of ~1.07 represents a modest individual effect, but the A allele frequency of ~17–23% in Europeans means a large proportion of the population carries at least one copy. For AG heterozygotes, this variant is best understood as a mild modifier of baseline thrombotic risk — most relevant when combined with other thrombophilic variants, traditional VTE risk factors (obesity, immobility, oral contraceptives, surgery, cancer), or family history.

AA homozygotes carry approximately doubled allele dosage. The additive architecture of the association means two copies confer meaningfully higher risk than one — though the absolute risk increment remains smaller than classical thrombophilia mutations like Factor V Leiden or prothrombin G20210A.

This variant is not included on standard thrombophilia panels. Clinicians performing thrombophilia workup after unprovoked VTE will not find it on coagulation assays; awareness requires genetic testing. The fibrinolytic mechanism — PN-1 suppressing tPA and plasmin activity — also implies potentially different implications for thrombolytic therapy response compared to coagulation-pathway variants.

Interactions

rs13412535 converges on the same fibrinolytic arm targeted by Factor V Leiden (rs6025) and prothrombin G20210A (rs1799963), which act through the coagulation cascade upstream. Concurrent Factor V Leiden plus a SERPINE2 fibrinolysis variant creates a mechanistic double-hit: more thrombin generated AND slower clot dissolution. Antithrombin variants (rs121909547 SERPINC1) that reduce thrombin inhibition further compound this picture.

The fibrinolytic suppression mechanism may also interact with SERPINE1 (PAI-1) variants — if both PAI-1 and PN-1 activity are elevated, the combined resistance to plasmin-mediated clot dissolution would be additive.

The [LDLR gene | low-density lipoprotein receptor gene; mutations cause familial hypercholesterolemia (FH), one of the most common serious inherited disorders, affecting ~1 in 250 people worldwide] is the master regulator of LDL cholesterol clearance from the bloodstream. The LDLR protein captures LDL particles circulating in blood and shuttles them into liver cells for degradation, keeping circulating LDL-C in check. When LDLR function is reduced or absent — as in classical FH — LDL-C accumulates and accelerates atherosclerosis.

rs137853964 sits in exon 18 of LDLR at chromosome 19 position 11,129,602 (GRCh38). This single nucleotide position carries two possible alternate alleles: G>A (producing Val827Ile) and G>T (producing Val827Phe). Both affect the same amino acid in the same functionally important domain, but they carry meaningfully different evidence profiles. The G>A change (Val827Ile) is the far more common variant; the G>T change (Val827Phe) is extremely rare.

The Mechanism

Position 827 of the LDLR protein lies within the [NPXY internalization motif | A short amino acid sequence (Asn-Pro-X-Tyr, where X is any amino acid) located in the cytoplasmic tail of LDLR at residues 823–828. This signal is recognized by clathrin adaptor proteins (AP-2), which concentrate LDL receptors into clathrin-coated pits for endocytosis. Disrupting NPXY prevents receptor internalization, trapping LDLR at the cell surface where it cannot deliver LDL for degradation] of the receptor's cytoplasmic tail. The NPXY sequence (amino acids 823–828) is the docking signal that allows the receptor, once it has captured an LDL particle at the cell surface, to be internalized into the cell via clathrin-coated pits.

Mutations in the NPXY motif classically impair receptor internalization — even if the LDL-binding domain remains intact, the receptor gets "stuck" at the cell surface and cannot recycle LDL into the cell. However, the position of Val827 within the NPXY sequence matters: the ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel noted that position 827 "is variable" within the NPXY signal, meaning not every amino acid at this position is equally constrained.

Thormaehlen et al. 2015¹¹ Thormaehlen et al. 2015
Systematic cell-based phenotyping of missense alleles empowers rare variant association studies: a case for LDLR and myocardial infarction performed functional LDL uptake assays on 253 LDLR missense variants. Val827Ile (G>A) showed no significant effect on LDL uptake, placing it in the "functionally benign" category despite its location in the NPXY motif. The Val827Phe change (G>T) has not been studied in functional assays; its REVEL score of 0.86 suggests possible damaging effects, and it has been observed in two Moroccan individuals with clinical FH.

The Evidence

The two variants at rs137853964 have divergent evidence:

Val827Ile (G>A) — the common alternate: The ClinGen FH Variant Curation Expert Panel²² ClinGen FH Variant Curation Expert Panel
an expert panel applying ACMG/AMP criteria specifically calibrated for FH variants, using ClinGen's CSpec framework for LDLR classified Val827Ile as uncertain significance in June 2021, applying evidence codes PP1 (segregation with FH phenotype in 3 informative meioses) and PP3 (REVEL 0.771 exceeds the 0.75 threshold). Competing evidence from 7 submissions of Likely Benign or Benign classification reflects the functional assay null result and the striking Ashkenazi Jewish enrichment (~1.44% allele frequency — approximately 14-fold above the expected maximum frequency for a typical FH-causing variant). One homozygous individual has been identified in the Ashkenazi Jewish population without apparent severe FH, further undermining pathogenic classification.

Sun et al. 2018³³ Sun et al. 2018
Effects of Genetic Variants Associated with FH on LDL-C and Cardiovascular Outcomes in the Million Veteran Program demonstrated that LDLR variants with null functional assay results are indistinguishable from non-carriers in terms of LDL-C levels and cardiovascular event rates in population-scale data. This strongly argues that Val827Ile, with its confirmed null functional result, does not cause clinically meaningful LDL receptor impairment.

Val827Phe (G>T) — the rare alternate: The G>T change has five ClinVar submissions: two Likely Pathogenic (Invitae/Labcorp, Centre de Génétique Moléculaire) and three Uncertain Significance (ClinGen Expert Panel, Broad Institute, All of Us). It is [absent from gnomAD | not observed in ~800,000 population-control alleles], consistent with it being extremely rare. Alhababi et al. 2018⁴⁴ Alhababi et al. 2018
Spectrum of mutations of FH in Arab countries reported it in 2 Moroccan FH patients. Without functional assay data, pathogenicity cannot be confirmed, though the rarity and in silico predictions lean toward possible pathogenicity.

Practical Implications

For carriers of the common G>A change (Val827Ile): current evidence does not establish this as a disease-causing FH variant. The functional assay null result and high Ashkenazi Jewish frequency are strong arguments for clinical benignity, even though the ClinGen Expert Panel maintains an uncertain significance classification pending additional segregation and functional data. If your lipid panel shows elevated LDL-C, investigate other causes — lifestyle, diet, secondary causes (thyroid, medications), or other FH genes (APOB, PCSK9).

For carriers of the rare G>T change (Val827Phe): the evidence leans toward possible pathogenicity, but formal confirmation is lacking. Clinical lipid evaluation and cascade family screening are prudent steps while the scientific community accumulates more data.

In both cases, LDL-C measurement is more immediately actionable than genotype alone for determining whether lipid-lowering intervention is warranted.

Interactions

LDLR variants interact with other genes in the LDL clearance pathway. Carrying rs137853964 alongside variants in:

• PCSK9 (rs11591147 R46L) — PCSK9 loss-of-function variants lower LDL by reducing LDLR degradation. If Val827Ile proves benign, a PCSK9 R46L carrier will have an unchanged cardioprotective benefit.
• APOB (rs693, rs5742904) — APOB mutations reduce LDL-receptor binding affinity, compounding any LDL clearance deficit. If both APOB and LDLR are affected, LDL-C elevation would be expected to be more severe.
• APOE ε4 (rs429358) — APOE4 raises LDL and cardiovascular risk independently of LDLR, and compound FH+APOE4 genotypes are associated with particularly aggressive atherosclerosis.

If Val827Ile is eventually reclassified as benign, these interaction considerations become moot for this variant. If Val827Phe is confirmed pathogenic, compound heterozygosity with other LDLR variants would carry significantly elevated risk of severe FH.